LAG3 is an immune checkpoint receptor known to suppress T cell activation. We designed ES005  to block  LAG3 ligands, including  MHC class II and FGL1. Through unique epitope binding, ES005  is able to recognize human LAG3 with high affinity. In preclinical studies, ES005 inhibited tumor growth both as a monotherapy and in combination with a PD-1 blocker.


ES005 is currently being evaluated in IND-enabling studies.